Masataka Kuwana

List of Publications by Year
in descending order

197	12,473	30551 56	32181 105
papers	citations	h-index	g-index

197	197	197	8283
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies. Clinical Reviews in Allergy and Immunology, 2023, 64, 239-261.	2.9	20
2	Cost-effectiveness analyses of biologic and targeted synthetic disease-modifying anti-rheumatic diseases in patients with rheumatoid arthritis: Three approaches with a cohort simulation and real-world data. Modern Rheumatology, 2023, 33, 302-311.	0.9	4
3	A multianalyte assay for the detection of dermatomyositis-related autoantibodies based on immunoprecipitation combined with immunoblotting. Modern Rheumatology, 2023, 33, 543-548.	0.9	5
4	Efficacy and safety of TNF-Î± antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients. Rheumatology, 2022, 61, 1376-1384.	0.9	26
5	Antiviral proinflammatory phenotype of monocytes in anti-MDA5 antibody-associated interstitial lung disease. Rheumatology, 2022, 61, 806-814.	0.9	23
6	Use of vonoprazan, a novel potassium-competitive acid blocker, for the treatment of proton pump inhibitor-refractory reflux esophagitis in patients with systemic sclerosis. Journal of Scleroderma and Related Disorders, 2022, 7, 57-61.	1.0	7
7	The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19. Rheumatology, 2022, 61, 1600-1609.	0.9	53
8	Nintedanib in Patients With Systemic Sclerosisâ€“Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score. Arthritis and Rheumatology, 2022, 74, 518-526.	2.9	21
9	Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition. Journal of Scleroderma and Related Disorders, 2022, 7, 24-32.	1.0	25
10	COVID-19 vaccination in autoimmune disease (COVAD) survey protocol. Rheumatology International, 2022, 42, 23-29.	1.5	37
11	Should we reconsider the definition of elderly-onset rheumatoid arthritis in an ageing society?. Modern Rheumatology, 2022, 32, 323-329.	0.9	6
12	Development of an Automated Chemiluminescent Enzyme Immunoassay for Measuring Thrombopoietin in Human Plasma. Diagnostics, 2022, 12, 313.	1.3	2
13	Outcomes in patients with systemic sclerosis undergoing early vs delayed intervention with potential disease-modifying therapies. Rheumatology, 2022, 61, 3677-3685.	0.9	5
14	Vaccine hesitancy in patients with autoimmune diseases: Data from the coronavirus disease-2019 vaccination in autoimmune diseases study. Indian Journal of Rheumatology, 2022, 17, 188.	0.2	14
15	Branched chain amino acids in the treatment of polymyositis and dermatomyositis: a phase II/III, multi-centre, randomized controlled trial. Rheumatology, 2022, , .	0.9	0
16	Clinical worsening following discontinuation of tocilizumab in diffuse cutaneous systemic sclerosis: a single-centre experience in Japan. Rheumatology, 2022, 61, 4491-4496.	0.9	9
17	Incidence Rate and Prevalence of Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease in Japan: Analysis Using Japanese Claims Databases. Advances in Therapy, 2022, 39, 2222-2235.	1.3	9
18	Presence and Implications of <scp>Antiâ€Angiotensin Converting Enzymeâ€2</scp> Immunoglobulin M Antibodies in <scp>Antiâ€Melanomaâ€Differentiationâ€Associated</scp> 5 Dermatomyositis. ACR Open Rheumatology, 2022, 4, 457-463.	0.9	4

#	Article	IF	Citations
19	Immune-mediated thrombotic thrombocytopenic purpura and HLA. Major Histocompatibility Complex, 2022, 29, 42-51.	0.2	0
20	Mortality Risk Stratification Using Cluster Analysis in Patients With Myositis-Associated Interstitial Lung Disease Receiving Initial Triple-Combination Therapy. Frontiers in Medicine, 2022, 9, .	1.2	5
21	COVID-19 vaccination-related adverse events among autoimmune disease patients: results from the COVAD study. Rheumatology, 2022, 62, 65-76.	0.9	19
22	Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: A Japanese population analysis of the SENSCIS trial. Modern Rheumatology, 2021, 31, 141-150.	0.9	14
23	Initial predictors of skin thickness progression in patients with diffuse cutaneous systemic sclerosis: Results from a multicentre prospective cohort in Japan. Modern Rheumatology, 2021, 31, 386-393.	0.9	6
24	Chest wall muscle atrophy as a contributory factor for forced vital capacity decline in systemic sclerosis-associated interstitial lung disease. Rheumatology, 2021, 60, 250-255.	0.9	12
25	Infection or Autoimmunity? The Clinical Challenge of Interstitial Lung Disease in Systemic Sclerosis During the COVID-19 Pandemic. Journal of Rheumatology, 2021, 48, 790-792.	1.0	2
26	Efficacy and safety of nintedanib in Asian patients with systemic sclerosis-associated interstitial lung disease: Subgroup analysis of the SENSCIS trial. Respiratory Investigation, 2021, 59, 252-259.	0.9	15
27	Current monitoring and treatment of progressive fibrosing interstitial lung disease: a survey of physicians in Japan, the United States, and the European Union. Current Medical Research and Opinion, 2021, 37, 327-339.	0.9	5
28	Risk Prediction Modeling Based on a Combination of Initial Serum Biomarker Levels in Polymyositis/Dermatomyositisâ€“Associated Interstitial Lung Disease. Arthritis and Rheumatology, 2021, 73, 677-686.	2.9	60
29	2019 Diagnostic criteria for mixed connective tissue disease (MCTD): From the Japan research committee of the ministry of health, labor, and welfare for systemic autoimmune diseases. Modern Rheumatology, 2021, 31, 29-33.	0.9	49
30	Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. Lancet Respiratory Medicine,the, 2021, 9, 96-106.	5.2	118
31	Clinical impact of myositis-specific autoantibodies on long-term prognosis of juvenile idiopathic inflammatory myopathies: multicentre study. Rheumatology, 2021, 60, 4821-4831.	0.9	12
32	Joint contractures responsive to immunosuppressive therapy in a girl with childhoodâ€onset systemic sclerosis doubleâ€seropositive for rare antiâ€nucleolar autoantibodies: a case report. Pediatric Rheumatology, 2021, 19, 37.	0.9	0
33	Infratentorial onset of progressive multifocal leukoencephalopathy in a patient with systematic lupus erythematosus complicated with lymphoma: a case report. Modern Rheumatology Case Reports, 2021, 5, 272-277.	0.3	3
34	Updates on genetics in systemic sclerosis. Inflammation and Regeneration, 2021, 41, 17.	1.5	15
35	Clinical characteristics of four myositis-specific autoantibodies with regulatory-approved testing in Japan: A Japanese multi-centre adult myositis patientsâ€™ cohort. Journal of Dermatological Science, 2021, 103, 53-56.	1.0	1
36	2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease. Respiratory Investigation, 2021, 59, 709-740.	0.9	45

#	Article	IF	Citations
37	Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial. Respiratory Medicine, 2021, 187, 106574.	1.3	6
38	Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110324.	1.2	30
39	Clinical Relevance of the Serial Measurement of Krebs von den Lungen-6 Levels in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease. Diagnostics, 2021, 11, 2007.	1.3	6
40	The development of quality indicators for systemic lupus erythematosus using electronic health data: A modified RAND appropriateness method. Modern Rheumatology, 2020, 30, 525-531.	0.9	6
41	Nintedanib: New indication for systemic sclerosis-associated interstitial lung disease. Modern Rheumatology, 2020, 30, 225-231.	0.9	29
42	Current understanding and recent advances in myositis-specific and -associated autoantibodies detected in patients with dermatomyositis. Expert Review of Clinical Immunology, 2020, 16, 79-89.	1.3	14
43	Reference guide for management of adult immune thrombocytopenia in Japan: 2019 Revision. International Journal of Hematology, 2020, 111, 329-351.	0.7	38
44	Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respiratory Medicine,the, 2020, 8, 963-974.	5.2	348
45	Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. Annals of the Rheumatic Diseases, 2020, 79, 724-726.	0.5	51
46	Performance evaluation of a commercial line blot assay system for detection of myositis- and systemic sclerosis-related autoantibodies. Clinical Rheumatology, 2020, 39, 3489-3497.	1.0	21
47	The promise, perceptions, and pitfalls of immunoassays for autoantibody testing in myositis. Arthritis Research and Therapy, 2020, 22, 117.	1.6	27
48	HLA loci predisposing to immune TTP in Japanese: potential role of the shared ADAMTS13 peptide bound to different HLA-DR. Blood, 2020, 135, 2413-2419.	0.6	22
49	Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease. Expert Review of Clinical Immunology, 2020, 16, 547-560.	1.3	5
50	Seasonal and residential clustering at disease onset of anti-MDA5-associated interstitial lung disease. RMD Open, 2020, 6, e001202.	1.8	37
51	Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic Sclerosis. Arthritis and Rheumatology, 2020, 72, 1049-1058.	2.9	27
52	Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype. Chest, 2020, 158, 646-659.	0.4	79
53	A unique thymus-derived regulatory T cell subset associated with systemic lupus erythematosus. Arthritis Research and Therapy, 2020, 22, 88.	1.6	14
54	Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis. Annals of the Rheumatic Diseases, 2020, 79, 626-634.	0.5	34

#	Article	IF	Citations
55	Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. Annals of the Rheumatic Diseases, 2020, 79, 618-625.	0.5	71
56	Risk factors for skin, mucosal, and organ bleeding in adults with primary ITP: a nationwide study in Japan. Blood Advances, 2020, 4, 1648-1655.	2.5	17
57	Recent progress and missing gaps to achieve goal in the care of systemic sclerosisâ€“associated interstitial lung disease. Journal of Scleroderma and Related Disorders, 2020, 5, 3-5.	1.0	9
58	Endothelial cells and endothelial progenitor cells in the pathogenesis of systemic sclerosis. European Journal of Rheumatology, 2020, 7, 139-146.	1.3	17
59	Dermatomyositis-Associated Autoantibodies: TIF1-Î³, NXP2, and MDA5. , 2020, , 193-198.		2
60	Role of Myositis Autoantibodies in Management and Prognosis. , 2020, , 175-180.		1
61	Predictive factors for sustained remission with stratification by myositis-specific autoantibodies in adult polymyositis/dermatomyositis. Rheumatology, 2019, 59, 586-593.	0.9	3
62	Performance evaluation of a line blot assay system for detection of antiâ€PMâ€Scl antibody in Japanese patients with systemic sclerosis. International Journal of Rheumatic Diseases, 2019, 22, 1746-1751.	0.9	7
63	Fos-related antigen-1 transgenic mouse as a model for systemic sclerosis: A potential role of M2 polarization. Journal of Scleroderma and Related Disorders, 2019, 4, 137-148.	1.0	0
64	Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18. Arthritis and Rheumatology, 2019, 71, 2059-2067.	2.9	55
65	Nintedanib for Systemic Sclerosisâ€“Associated Interstitial Lung Disease. New England Journal of Medicine, 2019, 380, 2518-2528.	13.9	1,025
66	Two cases with autoantibodies to small ubiquitinâ€like modifier activating enzyme: A potential unique subset of dermatomyositisâ€associated interstitial lung disease. International Journal of Rheumatic Diseases, 2019, 22, 1582-1586.	0.9	11
67	Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Annals of the Rheumatic Diseases, 2019, 78, 979-987.	0.5	142
68	Guidelines for the Treatment of Pulmonary Hypertension (JCS 2017/JPCPHS 2017). Circulation Journal, 2019, 83, 842-945.	0.7	132
69	Immune Checkpoint Inhibitor-Induced Myositis: a Case Report and Literature Review. Current Rheumatology Reports, 2019, 21, 10.	2.1	49
70	Anti-MDA5 antibody-positive rapidly progressive interstitial pneumonia without cutaneous manifestations. Respiratory Medicine Case Reports, 2019, 26, 193-196.	0.2	8
71	FRI0303â€…THE EFFECTS OF RIOCIGUAT ON RAYNAUDâ€™S PHENOMENON AND DIGITAL ULCERS IN PATIENTS WITH DIFFUSE SYSTEMIC SCLEROSIS: RESULTS FROM THE PHASE IIB RISE-SSC STUDY. , 2019, , .		0
72	OP0067â€…UTILITY OF RISK STRATIFICATION IN PREDICTING OUTCOMES OF INITIAL MONOTHERAPY VERSUS COMBINATION THERAPY IN PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH CONNECTIVE TISSUE DISEASE: A POST-HOC ANALYSIS OF THE AMBITION STUDY. , 2019, , .		0

#	Article	IF	Citations
73	OP0183â€…EFFICACY AND SAFETY OF RIOCIGUAT IN PATIENTS WITH EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS AND INTERSTITIAL LUNG DISEASE (SSC-ILD): RESULTS FROM THE PHASE IIB RISE-SSC STUDY. , 2019, , .		2
74	Cluster of differentiation 30 expression in lacrimal gland and conjunctival tissues in patients with SjÃ¶gren's syndrome. Medicine (United States), 2019, 98, e16390.	0.4	5
75	A case of cancerâ€associated myositis with antiâ€Miâ€2 antibody: Falseâ€positive antiâ€transcriptional intermediary factor 1â€Î³ antibody by commercial enzymeâ€linked immunosorbent assay. International Journal of Rheumatic Diseases, 2019, 22, 1335-1339.	0.9	3
76	Performance of Candidate Serum Biomarkers for Systemic Sclerosisâ€“Associated Interstitial Lung Disease. Arthritis and Rheumatology, 2019, 71, 972-982.	2.9	101
77	Add-on tocilizumab versus conventional treatment for systemic sclerosis, and cytokine analysis to identify an endotype to tocilizumab therapy. Modern Rheumatology, 2019, 29, 134-139.	0.9	12
78	Myositis-specific autoantibodies in Japanese patients with juvenile idiopathic inflammatory myopathies. Modern Rheumatology, 2019, 29, 351-356.	0.9	27
79	Improved quantification of a commercial enzyme-linked immunosorbent assay kit for measuring anti-MDA5 antibody. Modern Rheumatology, 2019, 29, 140-145.	0.9	8
80	T cells from induced and spontaneous models of SLE recognize a common T cell epitope on Î²2-glycoprotein I. Cellular and Molecular Immunology, 2019, 16, 685-693.	4.8	12
81	Next-Generation Sequencing of HLA Loci Identifies Predisposing and Protective Factors for Immune-Mediated Thrombotic Thrombocytopenic Purpura in a Japanese Population. Blood, 2019, 134, 1085-1085.	0.6	0
82	Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients. Rheumatology, 2018, 57, 1212-1221.	0.9	101
83	Evaluation of the alternative classification criteria of systemic lupus erythematosus established by Systemic Lupus International Collaborating Clinics (SLICC). Modern Rheumatology, 2018, 28, 642-648.	0.9	16
84	Î²2-Glycoprotein I-Reactive T Cells in Autoimmune Disease. Frontiers in Immunology, 2018, 9, 2836.	2.2	24
85	KL-6 But Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis-related Interstitial Lung Disease. Journal of Rheumatology, 2018, 45, 1153-1158.	1.0	56
86	Personalized medicine for connective tissue disease: Historical and future perspectives. Personalized Medicine Universe, 2018, 7, 1-6.	0.1	0
87	Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis. Respiratory Investigation, 2018, 56, 464-472.	0.9	25
88	Current understanding of the mechanisms for autoantibody production. Japanese Journal of Thrombosis and Hemostasis, 2018, 29, 243-250.	0.1	0
89	Three cases of interstitial pneumonia with anti-signal recognition particle antibody. Allergology International, 2017, 66, 485-487.	1.4	5
90	Antimelanoma Differentiation-associated Gene 5 Antibody: Expanding the Clinical Spectrum in North American Patients with Dermatomyositis. Journal of Rheumatology, 2017, 44, 319-325.	1.0	112

#	Article	IF	Citations
91	Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Annals of the Rheumatic Diseases, 2017, 76, 1219-1227.	0.5	135
92	Mouse immune thrombocytopenia is associated with Th1 bias and expression of activating FcÎ³ receptors. International Journal of Hematology, 2017, 105, 598-605.	0.7	2
93	A To-Do List at Diagnosis of Systemic Sclerosis with Positive Anti-RNA Polymerase III Antibodies. Journal of Rheumatology, 2017, 44, 550-552.	1.0	8
94	RXRB Is an MHC-Encoded Susceptibility Gene Associated with Anti-Topoisomerase IÂAntibody-Positive Systemic Sclerosis. Journal of Investigative Dermatology, 2017, 137, 1878-1886.	0.3	3
95	Transethnic meta-analysis identifies GSDMA and PRDM1 as susceptibility genes to systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1150-1158.	0.5	77
96	Sarcoplasmic MxA expression. Neurology, 2017, 88, 493-500.	1.5	118
97	HLA-DRB1 Alleles as Genetic Risk Factors for the Development of Anti-MDA5 Antibodies in Patients with Dermatomyositis. Journal of Rheumatology, 2017, 44, 1389-1393.	1.0	37
98	Comparison of anti-OJ antibody detection assays between an immunoprecipitation assay and line blot assay. Modern Rheumatology, 2017, 27, 551-552.	0.9	16
99	Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease. Respiratory Investigation, 2017, 55, 24-32.	0.9	24
100	Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities. Journal of Scleroderma and Related Disorders, 2017, 2, 137-152.	1.0	243
101	Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis. Journal of Scleroderma and Related Disorders, 2017, 2, 11-18.	1.0	321
102	Complex Pathophysiology of Pulmonary Hypertension Associated with Systemic Sclerosis: Potential Unfavorable Effects of Vasodilators. Journal of Scleroderma and Related Disorders, 2017, 2, 92-99.	1.0	7
103	Circulating Anti-Nuclear Antibodies in Systemic Sclerosis: Utility in Diagnosis and Disease Subsetting. Journal of Nippon Medical School, 2017, 84, 56-63.	0.3	46
104	Coexistence of anti-melanoma differentiation-associated gene 5 and anti-aminoacyl-transfer RNA synthetase antibodies in a patient with dermatomyositis and rapidly progressive and relapsing interstitial lung disease. Modern Rheumatology Case Reports, 2017, 1, 3-8.	0.3	11
105	T-Cell Abnormalities. , 2017, , 63-72.		0
106	Clinical Utility of an Enzyme-Linked Immunosorbent Assay for Detecting Anti-Melanoma Differentiation-Associated Gene 5 Autoantibodies. PLoS ONE, 2016, 11, e0154285.	1.1	102
107	Association of psoriasis with Hashimoto's thyroiditis, SjÃ¶gren's syndrome and dermatomyositis. Journal of Dermatology, 2016, 43, 711-712.	0.6	14
108	What do we learn from immunomodulation in patients with immune thrombocytopenia?. Seminars in Hematology, 2016, 53, S27-S30.	1.8	2

#	Article	IF	Citations
109	Elevated Serum Krebs von den Lungen-6 in Early Disease Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease. Journal of Rheumatology, 2016, 43, 1825-1831.	1.0	74
110	Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis. Journal of Dermatological Science, 2016, 84, 272-281.	1.0	69
111	Choosing the right biomarkers to predict ILD in myositis. Nature Reviews Rheumatology, 2016, 12, 504-506.	3.5	31
112	Antiâ€“Melanoma Differentiationâ€“Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis. Arthritis Care and Research, 2016, 68, 689-694.	1.5	199
113	Gottron Papules and Gottron Sign with Ulceration: A Distinctive Cutaneous Feature in a Subset of Patients with Classic Dermatomyositis and Clinically Amyopathic Dermatomyositis. Journal of Rheumatology, 2016, 43, 1735-1742.	1.0	39
114	Clinical and serological features of patients with dermatomyositis complicated by spontaneous pneumomediastinum. Clinical Rheumatology, 2016, 35, 489-493.	1.0	46
115	17. Importance of Early Diagnosis and Treatment in Patients with Systemic Sclerosis. The Journal of the Japanese Society of Internal Medicine, 2016, 105, 1864-1869.	0.0	0
116	Endothelial Progenitor Cells. , 2016, , 39-56.		0
117	Tocilizumab is effective against polymyalgia rheumatica: experience in 13 intractable cases. RMD Open, 2015, 1, e000162.	1.8	21
118	Distinct profiles of myositis-specific autoantibodies in Chinese and Japanese patients with polymyositis/dermatomyositis. Clinical Rheumatology, 2015, 34, 1627-1631.	1.0	55
119	Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study. BMC Pulmonary Medicine, 2015, 15, 62.	0.8	4
120	Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients. Orphanet Journal of Rare Diseases, 2015, 10, 61.	1.2	156
121	Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. Rheumatology, 2015, 54, 784-791.	0.9	114
122	Serum interferon-Î± is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis. Modern Rheumatology, 2015, 25, 85-89.	0.9	66
123	Oral vasopressin receptor antagonist tolvaptan in right heart failure due to pulmonary hypertension. European Respiratory Journal, 2015, 46, 283-286.	3.1	8
124	Utility of dermatomyositis-specific autoantibodies for diagnosis and clinical subsetting. International Journal of Clinical Rheumatology, 2015, 10, 257-271.	0.3	4
125	Elevated Levels of Pentraxin 3 in Systemic Sclerosis: Associations With Vascular Manifestations and Defective Vasculogenesis. Arthritis and Rheumatology, 2015, 67, 498-507.	2.9	54
126	Rapid Initiation of Intravenous Epoprostenol Infusion Is the Favored Option in Patients with Advanced Pulmonary Arterial Hypertension. PLoS ONE, 2015, 10, e0121894.	1.1	5

#	Article	IF	Citations
127	High-dose intravenous immunoglobulin therapy for rapidly progressive interstitial pneumonitis accompanied by anti-melanoma differentiation-associated gene 5 antibody-positive amyopathic dermatomyositis. European Journal of Rheumatology, 2015, 2, 83-85.	1.3	23
128	A regulatory T cell-deficient mouse model as a useful tool for evaluating the pathophysiology of human immune thrombocytopenia. Japanese Journal of Thrombosis and Hemostasis, 2015, 26, 605-610.	0.1	0
129	Induction of immune tolerance to platelet antigen by short-term thrombopoietin treatment in a mouse model of immune thrombocytopenia. International Journal of Hematology, 2014, 100, 341-344.	0.7	30
130	Comparison of radioimmunoprecipitation versus antigen-specific assays for identification of myositis-specific autoantibodies in dermatomyositis patients. Modern Rheumatology, 2014, 24, 945-948.	0.9	32
131	Brief Report: Impaired In Vivo Neovascularization Capacity of Endothelial Progenitor Cells in Patients With Systemic Sclerosis. Arthritis and Rheumatology, 2014, 66, 1300-1305.	2.9	40
132	Autoantibodies to RuvBL1 and RuvBL2: A Novel Systemic Sclerosisâ€"Related Antibody Associated With Diffuse Cutaneous and Skeletal Muscle Involvement. Arthritis Care and Research, 2014, 66, 575-584.	1.5	86
133	Distinct arthropathies of the hands in patients with anti-aminoacyl tRNA synthetase antibodies: usefulness of autoantibody profiles in classifying patients. Rheumatology, 2014, 53, 1120-1124.	0.9	8
134	Discordance in Global Assessments Between Patient and Estimator in Patients with Newly Diagnosed Rheumatoid Arthritis: Associations with Progressive Joint Destruction and Functional Impairment. Journal of Rheumatology, 2014, 41, 1061-1066.	1.0	34
135	Clinical and histological findings associated with autoantibodies detected by RNA immunoprecipitation in inflammatory myopathies. Journal of Neuroimmunology, 2014, 274, 202-208.	1.1	53
136	Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Rheumatology, 2014, 53, 2196-2203.	0.9	153
137	Versican is upregulated in circulating monocytes in patients with systemic sclerosis and amplifies a CCL2-mediated pathogenic loop. Arthritis Research and Therapy, 2013, 15, R74.	1.6	38
138	Early diagnosis and treatment for remission of clinically amyopathic dermatomyositis complicated by rapid progress interstitial lung disease: a report of two cases. Modern Rheumatology, 2013, 23, 190-194.	0.9	21
139	PLD4 as a novel susceptibility gene for systemic sclerosis in a Japanese population. Arthritis and Rheumatism, 2013, 65, 472-480.	6.7	62
140	Utility of Antiâ€"Melanoma Differentiationâ€"Associated Gene 5 Antibody Measurement in Identifying Patients With Dermatomyositis and a High Risk for Developing Rapidly Progressive Interstitial Lung Disease: A Review of the Literature and a Metaâ€Analysis. Arthritis Care and Research, 2013, 65, 1316-1324.	1.5	223
141	CD4+CD25+Foxp3+ Regulatory T Cells in the Pathophysiology of Immune Thrombocytopenia. Seminars in Hematology, 2013, 50, S43-S49.	1.8	82
142	Serum chemokine levels as prognostic markers in patients with early systemic sclerosis: a multicenter, prospective, observational study. Modern Rheumatology, 2013, 23, 1076-1084.	0.9	28
143	Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Modern Rheumatology, 2013, 23, 496-502.	0.9	170
144	Fcî³ receptor IIB gene polymorphism in adult Japanese patients with primary immune thrombocytopenia. Blood, 2013, 122, 1991-1992.	0.6	16

#	Article	IF	Citations
145	Common and Distinct Clinical Features in Adult Patients with Anti-Aminoacyl-tRNA Synthetase Antibodies: Heterogeneity within the Syndrome. PLoS ONE, 2013, 8, e60442.	1.1	306
146	Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Modern Rheumatology, 2013, 23, 496-502.	0.9	84
147	Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology, 2012, 51, 1563-1570.	0.9	261
148	Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Annals of the Rheumatic Diseases, 2012, 71, 710-713.	0.5	220
149	Amyopathic dermatomyositis developing rapidly progressive interstitial lung disease with elevation of anti-CADM-140/MDA5 autoantibodies. Modern Rheumatology, 2012, 22, 625-629.	0.9	32
150	The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology, 2012, 51, 1278-1284.	0.9	252
151	Myopathy Associated With Antibodies to Signal Recognition Particle. Archives of Neurology, 2012, 69, 728-32.	4.9	82
152	Brief Report: Association of HLAâ€“DRB1*0101/*0405 with susceptibility to antiâ€“melanoma differentiationâ€“associated gene 5 antibodyâ€“positive dermatomyositis in the Japanese population. Arthritis and Rheumatism, 2012, 64, 3736-3740.	6.7	78
153	Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of antiâ€“melanoma differentiationâ€“associated gene 5 antibody. Arthritis Care and Research, 2012, 64, 1602-1610.	1.5	156
154	Human Pentraxin 3 (PTX3) as a Novel Biomarker for the Diagnosis of Pulmonary Arterial Hypertension. PLoS ONE, 2012, 7, e45834.	1.1	42
155	Quantification of circulating endothelial progenitor cells in systemic sclerosis: a direct comparison of protocols. Annals of the Rheumatic Diseases, 2012, 71, 617-620.	0.5	33
156	Critical role of CD4+CD25+ regulatory T cells in preventing murine autoantibody-mediated thrombocytopenia. Experimental Hematology, 2012, 40, 279-289.	0.2	47
157	Serum ferritin correlates with activity of anti-MDA5 antibody-associated acute interstitial lung disease as a complication of dermatomyositis. Modern Rheumatology, 2011, 21, 223-227.	0.9	51
158	Analysis of dermatomyositisâ€specific autoantibodies and clinical characteristics in Japanese patients. Journal of Dermatology, 2011, 38, 973-979.	0.6	55
159	Anti-Melanoma Differentiation-Associated Gene 5 Antibody is a Diagnostic and Predictive Marker for Interstitial Lung Diseases Associated with Juvenile Dermatomyositis. Journal of Pediatrics, 2011, 158, 675-677.	0.9	79
160	Epidemiology of primary immune thrombocytopenia in children and adults in Japan: a population-based study and literature review. International Journal of Hematology, 2011, 93, 329-335.	0.7	76
161	Sensitivity and specificity of 2010 rheumatoid arthritis classification criteria. Rheumatology, 2011, 50, 1268-1274.	0.9	68
162	Clinical Correlations With Dermatomyositis-Specific Autoantibodies in Adult Japanese Patients With Dermatomyositis. Archives of Dermatology, 2011, 147, 391.	1.7	293

#	Article	IF	Citations
163	Clinically amyopathic dermatomyositis. Current Opinion in Rheumatology, 2010, 22, 639-643.	2.0	90
164	Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology, 2010, 49, 1713-1719.	0.9	261
165	Enhanced angiogenic potency of monocytic endothelial progenitor cells in patients with systemic sclerosis. Arthritis Research and Therapy, 2010, 12, R205.	1.6	33
166	Antiâ€“U11/U12 RNP antibodies in systemic sclerosis: A new serologic marker associated with pulmonary fibrosis. Arthritis and Rheumatism, 2009, 61, 958-965.	6.7	105
167	RNA helicase encoded by melanoma differentiationâ€“associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. Arthritis and Rheumatism, 2009, 60, 2193-2200.	6.7	511
168	Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review. Haematologica, 2009, 94, 850-856.	1.7	118
169	Helicobacter pylori eradication shifts monocyte FcÎ³ receptor balance toward inhibitory FcÎ³RIIB in immune thrombocytopenic purpura patients. Journal of Clinical Investigation, 2008, 118, 2939-49.	3.9	114
170	Inflammation and pathogenic fibrosis in human ocular chronic graft versus host disease. Inflammation and Regeneration, 2008, 28, 529-536.	1.5	1
171	Identification of Molecular Factors Required for Transdifferentiation of Human Circulating Monocytes into Multipotential Cells.. Blood, 2007, 110, 2408-2408.	0.6	3
172	Clinical evaluation of anti-aminoacyl tRNA synthetase antibodies in Japanese patients with dermatomyositis. Journal of Rheumatology, 2007, 34, 1012-8.	1.0	62
173	Endothelial Differentiation Potential of Human Monocyte-Derived Multipotential Cells. Stem Cells, 2006, 24, 2733-2743.	1.4	116
174	Effects of a Helicobacter pylori eradication regimen on anti-platelet autoantibody response in infected and uninfected patients with idiopathic thrombocytopenic purpura. Haematologica, 2006, 91, 1436-7.	1.7	43
175	The Role of Autoreactive T-Cells in the Pathogenesis of Idiopathic Thrombocytopenic Purpura. International Journal of Hematology, 2005, 81, 106-112.	0.7	60
176	Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis and Rheumatism, 2005, 52, 1571-1576.	6.7	627
177	Initial laboratory findings useful for predicting the diagnosis of idiopathic thrombocytopenic purpura. American Journal of Medicine, 2005, 118, 1026-1033.	0.6	48
178	Splenic Macrophages Maintain the Anti-Platelet Autoimmune Response Via Uptake of Opsonized Platelets in Patients with Chronic ITP.. Blood, 2005, 106, 221-221.	0.6	2
179	Defective vasculogenesis in systemic sclerosis. Lancet, The, 2004, 364, 603-610.	6.3	261
180	Clinical Features and Effects of Eradication on Helicobacter Pylori Positive 207 ITP Cases in Japan.. Blood, 2004, 104, 2071-2071.	0.6	0

#	Article	IF	Citations
181	Therapeutic Action of Helicobacter pylori (H. pylori) Eradication in Patients with Chronic ITP - Lessons from Eradication Therapy on H. pylori-Negative Patients.. Blood, 2004, 104, 2070-2070.	0.6	0
182	Impaired Platelet Production and Autoantibody-Mediated Platelet Destruction Are Two Major Causes for Prolonged Thrombocytopenia after Allogeneic HSCT.. Blood, 2004, 104, 2256-2256.	0.6	0
183	Multi-Lineage Potential of Human Monocyte-Derived Mesenchymal Progenitors (MOMPs).. Blood, 2004, 104, 3595-3595.	0.6	0
184	Initial Laboratory Findings Useful for Predicting the Diagnosis of Chronic ITP: Results of a Multicenter Prospective Study.. Blood, 2004, 104, 2061-2061.	0.6	0
185	Human circulating CD14+monocytes as a source of progenitors that exhibit mesenchymal cell differentiation. Journal of Leukocyte Biology, 2003, 74, 833-845.	1.5	275
186	HLA class II alleles in systemic sclerosis patients with anti-RNA polymerase I/III antibody: associations with subunit reactivities. Journal of Rheumatology, 2003, 30, 2392-7.	1.0	14
187	Identification of an immunodominant epitope on RNA polymerase III recognized by systemic sclerosis sera: Application to enzyme-linked immunosorbent assay. Arthritis and Rheumatism, 2002, 46, 2742-2747.	6.7	44
188	Autoreactive T cells to topoisomerase I in monozygotic twins discordant for systemic sclerosis. Arthritis and Rheumatism, 2001, 44, 1654-1659.	6.7	43
189	T cells that are autoreactive to Î²2-glycoprotein I in patients with antiphospholipid syndrome and healthy individuals. Arthritis and Rheumatism, 2000, 43, 65-75.	6.7	70
190	Association of Functional Microsatellites in the Human Type I Collagen Î±2 Chain (COL1A2) Gene with Systemic Sclerosis. Biochemical and Biophysical Research Communications, 2000, 272, 36-40.	1.0	26
191	Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody. Arthritis and Rheumatism, 1999, 42, 465-474.	6.7	127
192	An immunodominant epitope on DNA topoisomerase I is conformational in nature: Heterogeneity in its recognition by systemic sclerosis sera. Arthritis and Rheumatism, 1999, 42, 1179-1188.	6.7	32
193	Autoantibodies to RNA polymerases recognize multiple subunits and demonstrate cross-reactivity with RNA polymerase complexes. Arthritis and Rheumatism, 1999, 42, 275-284.	6.7	32
194	Association of Human Leukocyte Antigen Class II Genes with Autoantibody Profiles, but not with Disease Susceptibility in Japanese Patients with Systemic Sclerosis.. Internal Medicine, 1999, 38, 336-344.	0.3	53
195	Clinical and Prognostic Associations Based on Serum Antinuclear Antibodies in Japanese Patients with Systemic Sclerosis. Arthritis and Rheumatism, 1994, 37, 75-83.	6.7	259
196	Racial differences in the distribution of systemic sclerosisâ€“related serum antinuclear antibodies. Arthritis and Rheumatism, 1994, 37, 902-906.	6.7	115
197	Severe digital ischemia as an unrecognized manifestation in patients with antisynthetase autoantibodies: Case series and systematic literature review. Journal of Scleroderma and Related Disorders, 0, , 239719832210908.	1.0	0